We reviewed relevant data about the role of multigene assays in tailoring the decision-making for adjuvant chemotherapy for patients with ER+/HER2- early breast cancer and provided our viewpoint on specific topics regarding the optimal use of these assays in clinical practice. This evidence concerns the gene ESR1 and breast cancer.